Point72 Asia Singapore Pte. Ltd. Buys New Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,328 shares of the company's stock, valued at approximately $671,000.

A number of other hedge funds have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of IDEXX Laboratories by 0.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company's stock valued at $379,875,000 after buying an additional 2,463 shares in the last quarter. American Century Companies Inc. raised its holdings in IDEXX Laboratories by 46.0% during the second quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock worth $274,179,000 after buying an additional 177,226 shares during the last quarter. International Assets Investment Management LLC grew its stake in shares of IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after acquiring an additional 527,460 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of IDEXX Laboratories by 13.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company's stock worth $249,855,000 after purchasing an additional 59,519 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in IDEXX Laboratories by 4.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 406,086 shares of the company's stock valued at $205,163,000 after buying an additional 15,521 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Up 1.4 %

NASDAQ IDXX traded up $5.95 on Monday, hitting $427.70. The company's stock had a trading volume of 305,035 shares, compared to its average volume of 504,801. The company's 50-day moving average is $451.91 and its 200 day moving average is $477.31. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm has a market cap of $35.02 billion, a PE ratio of 40.67, a PEG ratio of 3.68 and a beta of 1.36. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.53 earnings per share. As a group, analysts predict that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the business's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.11% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on IDXX shares. Piper Sandler restated a "neutral" rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Leerink Partners started coverage on shares of IDEXX Laboratories in a report on Monday. They issued an "outperform" rating and a $500.00 target price on the stock. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday. JPMorgan Chase & Co. reduced their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Finally, Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $546.56.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.